Últimas noticias sobre Innate Pharma (NASDAQ:IPHA) Bolsa

Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Innate Pharma S.A. - American Depositary Shares

Innate Pharma SA

Starbucks Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) is scaling back on promotions under new CEO Brian Niccol. The company is focusing on premium coffee after a year of heavy discounting, the Wall Street Journal <a target="_blank" href="https://www.wsj.com/business/hospitality/starbucks-coffee-discounts-strategy-ceo-dcbde38b?mod=business_lead_pos1" rel="noreferrer noopener">reports</a>.
Since Niccol's appointment in August, the coffee chain has reduced its discounts, aiming to improve in-store experiences and reinforce its premium image, the WSJ cites company executives and baristas.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/09/40892040/starbucks-north-america-ceo-michael-conway-quits-after-just-6-months-in-the-position" rel="noreferrer noopener">Starbucks North America CEO Michael Conway Quits After Just 6 Months In The Position</a>
In September, Brian Niccol, on his second day as Starbucks CEO, <a target="_blank" href="https://www.benzinga.com//node/40809142" rel="noreferrer noopener">announced plans</a> to return the company to its roots as a community coffeehouse.
Niccol is known for turning around Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) and Taco Bell, which is owned by Yum! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) is Starbucks' fourth CEO in two years. He takes over amid declining sales and pressure from employees and investors.
Starbucks has experienced falling sales for two consecutive quarters. Customers have complained about high prices, slow app orders, and subpar food options.
The company has also faced union organizing efforts due to dissatisfaction with working conditions, pay, and benefits.
Now, the company has moved away from broad offers and will emphasize seasonal drinks through holiday advertising instead of discounts.
Under Niccol, the focus is shifting toward delivering high-quality, handcrafted coffee and improving customer service rather than relying on frequent offers and deals.
After years of raising menu prices, restaurant chains like Starbucks have increasingly used discounts this year to attract customers. Executives explained that price hikes were needed to offset rising costs and wages.
Starbucks' <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/40051434/starbucks-q3-earnings-revenue-miss-eps-in-line-comps-down-3-action-plan-is-beginning-to-work" rel="noreferrer noopener">third-quarter revenue</a> was $9.10 billion, lagging the&nbsp;analyst consensus estimate of $9.24 billion. The company reported EPS of $0.93, in line with consensus analyst estimates. Comparable store sales declined 3% due to a&nbsp;5%&nbsp;decline in comparable transactions.
Starbucks&nbsp;stock gained over 2% in the last 12 months. In September, Jefferies analyst Andy Barish downgraded Starbucks from Hold to Underperform and lowered the <a target="_blank" href="https://www.benzinga.com/quote/SBUX/analyst-ratings" rel="noreferrer noopener">price target from&nbsp;$80&nbsp;to&nbsp;$76</a>.
Investors can gain exposure to Starbucks through Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), and SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>).
<h2 class="wp-block-heading">Starbucks Stock Prediction For 2024</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of Starbucks have an average 1-year price target of $97.68, representing an expected upside of 2.23%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. 2 analysts have bearish recommendations on Starbucks, while 18 analysts have bullish ratings. The street high price target from Evercore ISI Group is $120.0, while the street low from Jefferies is $76.0.
Price Action: SBUX stock is down 0.26% at $95.30 premarket at the last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41163538/starbucks-invests-in-future-proof-coffee-new-farms-in-latin-america-and-beyond-to-tackle-climate" target="_blank" rel="noreferrer noopener">Starbucks Invests In Future-Proof Coffee: New Farms In Latin America And Beyond To Tackle Climate Challenges</a></li>
</ul>
Photo via Shutterstock

News

Media

SBUX

Starbucks Shifts Strategy: Fewer Deals, More Focus on Quality Coffee and Holiday Favorites

On Monday, Jasper Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) stock is trading higher after the company reported preliminary data from its ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with cold urticaria (ColdU) or <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41309952/jasper-therapeutics-reports-positive-data-from-spotlight-study-of-briquilimab-in-chronic-inducible" rel="noreferrer noopener">symptomatic dermographism (SD)</a>.
Hives (also called&nbsp;urticaria) refer to raised and splotchy areas of skin that can be caused by an allergic reaction.
14 of 15 study participants (93%) enrolled in both dose cohorts (n=15) achieved a clinical response within the 6-week preliminary analysis period following administration.
In the 120mg dose cohort, 10 of 12 participants (83%) experienced a complete response (CR), and 1 participant experienced a partial response (PR).
Briquilimab was well tolerated in the study, with no serious adverse events (SAEs) and no grade 3 or higher adverse events (AEs) reported.
In alignment with the company&#8217;s clinical development plan, Jasper has obtained regulatory clearance to enroll a 180mg dose cohort (n=12) in the SPOTLIGHT study.
Jasper expects to present full data from the SPOTLIGHT study in the first half of 2025.
Jasper also announced that it expects to report initial data from all cohorts of the BEACON study in CSU during the week of January 6th, 2025, including the recently added 180mg Q8W dose cohort.
Significant reductions in tryptase were observed as early as the week 1 assessment and were correlated with the onset of clinical responses.
The greatest reduction in mean tryptase of 66% was observed at 2 weeks following treatment in the 120mg cohort. At the week 6 assessment, the mean tryptase reduction observed was 31% below the baseline, and 7 of 12 participants (58%) enrolled in the 120mg cohort continued to maintain a clinical response (CR=6, PR=1).
Mild decreases in neutrophil counts were observed, with no participants experiencing neutrophil counts below 1500.
Price Action: JSPR stock is up 5.93% at $15.90 during the premarket session at last check Monday.
Illustration of Phrama lab worker created with MidJourney.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41296978/novo-nordisk-eli-lilly-could-face-downward-pressure-despite-market-dominance-from-p" target="_blank" rel="noreferrer noopener">Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names</a>.</li>
</ul>

Biotech

Equities

Health Care

Movers

Trading Ideas

General

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?

Stifel analyst Mark Kelley maintains Perion Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PERI#NASDAQ">PERI</a>) with a Hold and lowers the price target from $9 to $7.5.

Price Target

Analyst Ratings

PERI

Stifel Maintains Hold on Perion Network, Lowers Price Target to $7.5

<ul>
<li>Los Angeles Rams fans to enjoy augmented in-game Next Gen Stats highlights during games at SoFi Stadium, powered by GeniusIQ</li>
<li>Genius Sports to enhance fan experience with Next Gen Stats including player locators, time for the quarterback to throw, speeds and minimaps</li>
<li>Rams partner Verizon to sponsor the augmented content</li>
</ul>
The Los Angeles Rams ("Rams") have collaborated with Genius Sports Limited ("Genius Sports") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) to provide their fans with augmented, data-driven in-game highlights within SoFi Stadium.
During every Rams home game, immersive highlights leveraging the NFL's proprietary Next Gen Stats ("NGS") data will be displayed on SoFi Stadium's iconic Infinity Screen. These highlights, powered by GeniusIQ, Genius Sports' next generation data and artificial intelligence platform will include crucial NGS insights such as player locators and speeds, time for the quarterback to throw and a complete minimap.
As a long-term partner of the Rams, Verizon will be integrated at crucial times within the highlights, unlocking premium new augmented advertising inventory in front of a highly engaged audience. Verizon's logo and messaging will take center stagecreating a dynamic new platform for them to strengthen their brand affinity with Rams fans.
GeniusIQ applies powerful machine learning and AI to translate huge volumes of NGS data into a semantic understanding of football. It then powers real-time insights and brand activations, creating meaningful connections with fans when the on-field action is at its most compelling.

GENI

Los Angeles Rams Announces New Collaboration With Genius Sports, Launching Next Gen Stats-Powered, In-Stadium Highlights Powered By GeniusIQ

Stifel analyst Mark Kelley maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $590 to $663.

Stifel Maintains Buy on Meta Platforms, Raises Price Target to $663

UBS analyst Michael Goldsmith initiates coverage on Alpine Income Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINE#NYSE">PINE</a>) with a Neutral rating and announces Price Target of $19.

Initiation

PINE

UBS Initiates Coverage On Alpine Income Prop Trust with Neutral Rating, Announces Price Target of $19

A recent survey indicates that economists foresee a rise in inflation and federal deficits if former President Donald Trump returns to office, compared to Vice President Kamala Harris&#8216; policies.
What Happened: The survey conducted from Oct. 4-8, a majority of economists predict that inflation, interest rates, and deficits would escalate more under Trump&#8217;s economic strategies than under Harris&#8217;s proposals. This survey mirrors findings from July when Trump was competing against President Biden, who withdrew from the race on July 21, leading to Harris&#8217;s nomination, Wall Street Journal <a href="https://www.wsj.com/politics/elections/economists-say-inflation-deficits-will-be-higher-under-trump-than-harris-0365588e">reported</a> on Monday.
The survey results show that 68% of economists expect prices to rise more rapidly under Trump than Harris, an increase from 56% in July. Only 12% anticipate higher inflation under Harris, with the remainder seeing no significant difference. 
Dan Hamilton from California Lutheran University highlighted Trump&#8217;s tariff plans as a contributing factor, stating, &#8220;Since July, it became apparent to us that Trump is even more anti-free-trade than Harris.&#8221;
See Also: <a href="https://www.benzinga.com/news/24/10/41306291/trouble-for-kamala-harris-ahead-pennsylvania-north-carolina-nevada-democrats-lose-voter-registration?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trouble For Kamala Harris Ahead? Pennsylvania, North Carolina, Nevada: Democrats Lose Voter Registration</a>
Trump has proposed tariffs ranging from 10% to 20% on imports, with a 60% or higher tariff on Chinese goods. Economists argue these tariffs could lead to increased consumer costs. Philip Marey of Rabobank cautioned, &#8220;If the tariffs work the way economists think they work, I think people are in for a very nasty surprise.&#8221;
Additionally, 65% of economists predict Trump&#8217;s policies would increase the federal deficit, compared to 51% in July. The Committee for a Responsible Federal Budget estimates Trump&#8217;s plans could widen deficits by $7.5 trillion over the next decade, more than double the expected increase under Harris.
Why It Matters: Trump&#8217;s economic strategies have been a topic of discussion, particularly his focus on reducing energy costs to combat inflation. During an interview with financial expert Dave Ramsey, Trump emphasized the importance of <a href="https://www.benzinga.com/news/24/10/41183626/trump-tells-dave-ramsey-how-he-plans-to-lower-interest-rates-and-inflation-the-first-thing-you-have">lowering energy prices</a> to ease economic pressures and reduce interest rates. 
However, his plans for tax cuts, tariffs, and mass deportations have <a href="https://www.benzinga.com/personal-finance/24/09/40961812/economists-warn-trumps-plans-for-tax-cuts-tariffs-and-deportation-could-trigger-skyrocketing-inf">raised concerns among economists</a> about potential inflation spikes. At the New York Economic Club, Trump downplayed the costs of child care, focusing instead on the revenue he expects from tariffs, which he claims will bring in &#8220;trillions of dollars&#8221; for the U.S. government. 
Meanwhile, Scott Bessent, a key economic adviser to Trump, has defended the former <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41308042/trump-adviser-defends-ex-presidents-economic-policies-strong-dollar-would-natural">president&#8217;s economic policies</a>, assuring that a new Trump administration would support a strong dollar, contrary to previous suggestions of a weaker dollar to boost exports.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo via Shutterstock.
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Politics

Economics

Trump's Economic Policies Expected To Drive Inflation And Deficits Higher Than Harris,' Economists Say

Dolphin Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>), a leading entertainment marketing and premium content production company, today announced that the company will effect a 1-for-2 reverse split of its issued and outstanding shares of common stock. The reverse stock split will become effective October 16, 2024 at 12:01 a.m. EDT. Shares of the company's common stock will trade on a split-adjusted basis on The NASDAQ Capital Market, as of the opening of trading on Wednesday, October 16, 2024. The new CUSIP number for the Company's common stock will be 25686H 308.
The reverse stock split is being effected as part of the company's plan to regain compliance with the $1.00 minimum bid price continued listing requirement of The NASDAQ Capital Market and to have the additional authorized shares of common stock available to provide additional flexibility regarding the potential use of shares of common stock for business and financial purposes in the future.

Stock Split

DLPN

Dolphin Entertainment Announces 1-For-2 Reverse Stock Split, Will Trade On A Split-Adjusted Basis As Of The Opening Of Trading On Wednesday, October 16, 2024

Willdan Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDN#NASDAQ">WLDN</a>) announced today that the City of Seattle has awarded Willdan a four-year contract to implement its Seattle City Light Energy Design Assistance Program. Under this contract, Willdan will provide technical assistance that supports energy-efficient design decisions in the development of new multifamily and commercial buildings. Willdan will also partner and subcontract with qualified, local women- and minority-owned businesses, sharing knowledge and its NEO&#xAE; software – a simplified energy modeling tool – to demonstrate ways to enhance the businesses' current skillsets and broaden their impact in the industry.

WLDN

Willdan Selected By City Of Seattle For A 4-Year Contract To Implement Its Seattle City Light Energy Design Assistance Program; Financial Terms Not Disclosed

Stifel analyst Brian Butler reiterates Fastenal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) with a Buy and raises the price target from $80 to $86.

Reiteration

FAST

Stifel Reiterates Buy on Fastenal, Raises Price Target to $86

NTBL

Trading Halt: Halted at 9:17:54 a.m. ET - Trading Halt: Halt News Pending

WIIM

Melco Resorts & Entertainment Limited - American Depositary Shares

MLCO

Melco shares are trading lower following the election of Sam Hou-Fai as Macau's next leader. Sam Hou-Fai has reportedly called for diversifying Macau's industries beyond gambling.

Wedbush analyst David Chiaverini upgrades Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) from Underperform to Neutral and raises the price target from $10 to $45.

Upgrades

UPST

Wedbush Upgrades Upstart Hldgs to Neutral, Raises Price Target to $45

AeroVironment (AV), a global leader in intelligent, multi-domain robotic systems, announced today that the U.S. Army has awarded a $54.9 million delivery order for the production of Switchblade&#xAE; loitering munition systems. The recently announced award includes an additional contract ceiling of $743 million with $54.9 million in new funding. This contract is issued as part of a broader, previously executed, indefinite delivery, indefinite quantity contract, and ensures continued support for both the U.S. Army and several allied partners, including Lithuania, Romania, and Sweden.

Contracts

AVAV

AeroVironment Awarded A $54.9M Delivery Order For The Production Of Switchblade Loitering Munition Systems. The Recently Announced Award Includes An Additional Contract Ceiling Of $743M

UBS analyst Michael Goldsmith initiates coverage on Netstreit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTST#NYSE">NTST</a>) with a Buy rating and announces Price Target of $19.

NTST

UBS Initiates Coverage On Netstreit with Buy Rating, Announces Price Target of $19

<ul>
<li>TSLA</li>
<li>MSTR</li>
<li>NVDA</li>
<li>SOFI</li>
<li>WAY</li>
<li>DJT</li>
<li>MADE</li>
<li>LOT</li>
<li>CORN</li>
<li>BABA</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

BABA

CORN

MADE

MSTR

NVDA

SOFI

TSLA

Top 10 Trending Stocks On WallStreetBets As Of October 14, 2024 (Via Swaggy Stocks)

Shiba Inu's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) rising burn rates has traders speculating that the meme coin is getting ready for an <a href="https://www.benzinga.com/money/shiba-inu-price-prediction">upcoming price rally</a>.
What Happened: Shiba Inu's burn rate has skyrocketed by 14,575.02% since the last burn transaction of 277.6 million coins, according to Shibburn data. Amid the spike in burn rates, SHIB is up by 2.6% over the past 24 hours.
Crypto enthusiast &#8216;Chiara.sol&#8217; has set new targets for Shiba Inu over the weekend, seeing that the meme coin has "broken out of a bullish channel and a potential rally is taking shape."
He sees key resistance levels of $0.0000186494, $0.0000196923 and $0.0000209399. If these zones are cleared, SHIB could push to $0.000027 (+49% from current levels) in the upcoming days or weeks.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/SHIB?src=hash&amp;ref_src=twsrc%5Etfw">#SHIB</a> Shiba Inu has just broken out of a bullish channel, and a potential rally is taking shape. &#x1f4c8; The 60-minute chart shows a second accumulation phase forming a triangle pattern, supporting the case for a bullish move. Key resistance levels to watch: $0.0000186494… <a href="https://t.co/mLoIt7chsH">pic.twitter.com/mLoIt7chsH</a>
&mdash; Chiara.sol (@chiarapromos) <a href="https://twitter.com/chiarapromos/status/1845064889074602447?ref_src=twsrc%5Etfw">October 12, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41297116/whats-going-on-with-dogecoin-shiba-inu-today">What&#8217;s Going On With Dogecoin, Shiba Inu Today?</a>
Why It Matters: IntoTheBlock data shows large transaction volume decreasing by 55.9% and daily active addresses rising by 4.3%. Shiba Inu's concentration by large holders remains at 73%, implying high trader interest in the meme coin as a long term investment.
Heavily followed crypto influencer Ansem pointed out that, based on Etherscan <a href="https://etherscan.io/token/0x95ad61b0a150d79219dcf64e1e6cc01f0b64c4ce">data</a>, Shiba Inu has 1.4 million holders compared to the top meme coins on Solana, which have only 100,000 holders.
Benzinga technical analysis shows an RSI of 42.9 for SHIB, indicating that the meme coin is in an uptrend or bull market. The 50-day Simple Moving Average and 100-day Simple Moving Average are about to converge, implying that a significant price move could be in the making.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41243296/shiba-inu-lead-developer-shytoshi-kusama-reshares-mysterious-post-about-the-last-chapter-t">Shiba Inu Lead Developer Shytoshi Kusama Clears Air On Cryptic &#8216;The Last Chapter To My Story&#8217; Post (Updated)</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$SHIB

'Dogecoin Killer' Shiba Inu Incinerates 277M Coins In 1 Transaction: Watch These Levels For A Bullish Rally

Stifel analyst Mark Kelley maintains DoubleVerify Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) with a Buy and lowers the price target from $25 to $22.

Stifel Maintains Buy on DoubleVerify Hldgs, Lowers Price Target to $22

<a href="https://www.benzinga.com/news/24/09/40866217/openai-reportedly-plans-to-charge-2-000-monthly-for-elite-subscription-will-advanced-ai-access-be-wo">OpenAI</a>, the company behind the AI sensation ChatGPT, is again making headlines after securing $6.6 billion in one of the largest venture capital funding rounds in U.S. history.&nbsp;
According to The Wall Street Journal, this deal now values the San Francisco-based startup at a jaw-dropping $157 billion—on par with giants like Goldman Sachs, Uber and AT&amp;T. Big-name backers including Thrive Capital, Microsoft and Nvidia, the world's leading AI chipmaker, have placed their bets on OpenAI&#8217;s potential to reshape the future.
Don't Miss:
<ul>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
Interestingly, even Apple initially showed interest in the project. According to The Wall Street Journal, Apple discussed integrating ChatGPT with its new iPhone Intelligence system. However, those discussions eventually fizzled out and there was no official explanation.&nbsp;
This monumental funding surge heaps added pressure on OpenAI CEO <a href="https://www.benzinga.com/startups/24/09/41049190/busted-joe-rogan-openly-mocks-sam-altman-for-flexing-in-a-4-million-hyper-car-while-telling-everybod">Sam Altman</a>. According to WSJ, the clock is ticking. Originally founded as a nonprofit, OpenAI has only two years to fully transition into a for-profit entity, a change that has stirred debate among critics and supporters alike.&nbsp;
Trending: This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a>
Several experts have raised concerns that the drive to commercialize AI could lead to hasty releases of powerful tools before their risks are fully understood. Rushing to market could amplify societal risks—everything from privacy concerns to job displacement.
However, according to Bloomberg, Altman's vision remains clear: the new funds will be channeled to create a network of AI chip factories. OpenAI also aims to stay ahead of the competition to develop AI models that push the boundaries of humanlike reasoning.&nbsp;
Trending: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
The company's latest large language model, code-named "o1," is engineered to simulate human reasoning at new levels, marking a significant leap forward. However, OpenAI isn't the only player in the game. As Bloomberg also noted, <a href="https://www.benzinga.com/startups/24/06/39548316/alarming-google-study-of-gen-zers-theyre-spending-their-time-mindlessly-in-timepass-mode">Google </a>is investing heavily in AI to create models capable of handling intricate, multi-step problems, particularly in mathematics and coding.
However, not everyone is optimistic. Bloomberg cites renowned MIT economist Daron Acemoglu, who remains cautious about the AI hype, if not outright skeptical. Acemoglu argues that many claims about AI's potential to revolutionize industries are overly inflated.&nbsp;
He believes AI will likely automate no more than 5% of current jobs within the next decade – a far cry from the transformative promises echoing through Silicon Valley. "A lot of money will get wasted," Acemoglu warns, hinting at a tech bubble on the horizon.
Read Next:
<ul>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.</li>
</ul>

Startups

Investors Pour Billions Into OpenAI – What's Driving This Unprecedented Surge In Funding?

UBS analyst Matheus Enfeldt initiates coverage on Adecoagro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>) with a Neutral rating and announces Price Target of $12.

AGRO

UBS Initiates Coverage On Adecoagro with Neutral Rating, Announces Price Target of $12

Kepler Capital analyst Justine Telliez maintained a Hold rating on Innate Pharma SA (IPHYF – Research Report) on September 9 and set a price target...

Kepler Capital  Sticks to Its Hold Rating for Innate Pharma SA (IPHYF)

Innate Pharma GAAP EPS of -€0.31, revenue of €12.35M

Innate Pharma S.A. (IPHA) Q2 2024 Earnings Call Transcript

Goldman Sachs analyst Rajan Sharma has maintained their neutral stance on IPHYF stock, giving a Hold rating on September 9. Rajan Sharma has given ...

Hold Rating on Innate Pharma SA Amid FDA Discussions and Strategic Uncertainties

In a report released on September 12, Justine Telliez from Kepler Capital maintained a Hold rating on Innate Pharma SA (IPHYF – Research Report), w...

Kepler Capital  Reaffirms Their Hold Rating on Innate Pharma SA (IPHYF)

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Innate Pharma (IPHA – Research Report) on September 13 and set a price target of $5.00....

Innate Pharma (IPHA) Receives a Buy from Evercore ISI

Innate gets FDA clearance for Phase 1 study for IPH4502 ADC candidate

In a report released on September 26, Justine Telliez from Kepler Capital maintained a Hold rating on Innate Pharma SA (IPHYF – Research Report), w...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Innate Pharma (IPHA – Research Report) on October 4. The company's shares close...

Comments

Innate Pharma

Noticias

Últimas noticias sobre Innate Pharma (NASDAQ:IPHA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL